- Home
- CTW vs ENTX Comparison
CTW vs ENTX Comparison
Compare CTW & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTW
- ENTX
- Stock Information
- Founded
- CTW 2013
- ENTX 2010
- Country
- CTW Japan
- ENTX Israel
- Employees
- CTW N/A
- ENTX N/A
- Industry
- CTW EDP Services
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CTW Technology
- ENTX Health Care
- Exchange
- CTW Nasdaq
- ENTX Nasdaq
- Market Cap
- CTW 131.0M
- ENTX 142.0M
- IPO Year
- CTW 2025
- ENTX 2018
- Fundamental
- Price
- CTW $2.35
- ENTX $2.70
- Analyst Decision
- CTW
- ENTX Strong Buy
- Analyst Count
- CTW 0
- ENTX 1
- Target Price
- CTW N/A
- ENTX $10.00
- AVG Volume (30 Days)
- CTW 285.0K
- ENTX 253.9K
- Earning Date
- CTW 11-17-2025
- ENTX 11-14-2025
- Dividend Yield
- CTW N/A
- ENTX N/A
- EPS Growth
- CTW N/A
- ENTX N/A
- EPS
- CTW N/A
- ENTX N/A
- Revenue
- CTW $76,194,020.00
- ENTX $124,000.00
- Revenue This Year
- CTW N/A
- ENTX N/A
- Revenue Next Year
- CTW N/A
- ENTX N/A
- P/E Ratio
- CTW $51.43
- ENTX N/A
- Revenue Growth
- CTW 8.71
- ENTX 25.25
- 52 Week Low
- CTW $1.71
- ENTX $1.50
- 52 Week High
- CTW $4.88
- ENTX $3.22
- Technical
- Relative Strength Index (RSI)
- CTW N/A
- ENTX 51.38
- Support Level
- CTW N/A
- ENTX $2.61
- Resistance Level
- CTW N/A
- ENTX $3.22
- Average True Range (ATR)
- CTW 0.00
- ENTX 0.24
- MACD
- CTW 0.00
- ENTX -0.04
- Stochastic Oscillator
- CTW 0.00
- ENTX 29.87
About CTW CTW Cayman Class A Ordinary Shares
CTW Cayman is a web-based gaming platform, offering players an immersive digital space through flagship HTML5 platform, G123.jp. The company's primary focus is to serve game developers by providing a comprehensive platform that helps them generate revenue and reach a global audience. The platform offers a diverse selection of free-to-play games inspired by popular Japanese animations and it hosts 28 games, with 9 additional titles in pre-registration.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.